Study participant characteristics and phenotype assay or measure
| Factor and study acronym . | Ancestry . | No. of participants in study . | % Female . | Mean age, y . | Trait . | Assay/measure . | |
|---|---|---|---|---|---|---|---|
| Mean . | SD . | ||||||
| Fibrinogen (g/L) | |||||||
| ARIC49 | EUR | 10 757 | 53.1 | 54.3 | 2.90 | 1.21 | Clauss |
| AFR | 3 643 | 61.9 | 53.5 | 3.13 | 1.23 | ||
| CARDIA50 | EUR | 2 041 | 52.5 | 30.5 | 2.51 | 1.23 | Immunonephelometry |
| AFR | 1 709 | 56.9 | 29.4 | 2.66 | 1.23 | ||
| CHS51 | EUR | 4 034 | 56.2 | 72.8 | 3.13 | 1.22 | Clauss |
| AFR | 757 | 62.2 | 72.7 | 3.35 | 1.23 | ||
| FHS52,53 | EUR | 6 711 | 54.3 | 46.0 | 3.24 | 0.68 | Clauss |
| GeneSTAR54 | EUR | 1 091 | 51.2 | 41.2 | 3.51 | 0.98 | Modified Clauss |
| AFR | 641 | 61.9 | 40.6 | 3.80 | 1.12 | ||
| KORA S455,56 | EUR | 2 687 | 53.1 | 47.9 | 2.60 | 0.58 | Immunonephelometry |
| Korcula57 | EUR | 748 | 64.3 | 56.4 | 4.55 | 1.52 | Clauss |
| LBC 192158,59 | EUR | 466 | 57.4 | 79.1 | 3.59 | 0.86 | Clauss |
| LBC 193658,60 | EUR | 973 | 49.2 | 69.6 | 3.27 | 0.63 | Clauss |
| MESA61 | EUR | 2 483 | 52.1 | 62.7 | 3.35 | 0.7 | Immunonephelometry on the BN II nephelometer |
| AFR | 1 638 | 53.8 | 62.2 | 3.60 | 0.79 | ||
| ASI | 764 | 50.8 | 62.4 | 3.29 | 0.61 | ||
| HIS | 1 431 | 51.5 | 61.0 | 3.59 | 0.75 | ||
| PROCARDIS62 | EUR | 1 404 | 36.8 | 60.9 | 4.06 | 0.96 | Immunonephelometric |
| RS-I-163-65 | EUR | 1 114 | 59.0 | 70.2 | 2.70 | 1.26 | Prothrombin time |
| RS-I-363-65 | EUR | 972 | 46.7 | 72.4 | 3.96 | 0.89 | Prothrombin time |
| SCARF66 | EUR | 697 | 17.5 | 53.2 | 3.47 | 0.79 | Immunonephelometric |
| SHIP67 | EUR | 5 940 | 52.3 | 47.9 | 2.99 | 0.71 | Clauss |
| WGHS7,68 | EUR | 22 411 | 100 | 54.7 | 3.59 | 0.78 | Mass-based immunoturbidimetric assay |
| WHI69-71 | EUR | 1 204 | 100 | 69.6 | 3.06 | 0.86 | Clauss |
| FVII (% antigen or % activity)* | |||||||
| ARIC | EUR | 10 544 | 52.9 | 54.3 | 118.3 | 26.7 | Clotting assay (% activity) |
| AFR | 3 574 | 61.9 | 53.6 | 116.7 | 28.4 | ||
| CARDIA | EUR | 997 | 52.5 | 30.6 | 83.7 | 21.5 | Clotting assay (% activity) |
| AFR | 637 | 55.6 | 29.2 | 84.2 | 26.2 | ||
| CHS | EUR | 4 063 | 56.2 | 72.8 | 125.9 | 29.5 | Clotting assay (% activity) |
| AFR | 760 | 62.1 | 72.6 | 113.0 | 26.4 | ||
| FHS | EUR | 2 620 | 55.3 | 53.9 | 100.3 | 16.3 | ELISA (% antigen) |
| RS-I | EUR | 670 | 59.0 | 70.6 | 107.5 | 19.1 | Clotting assay (% activity) |
| SCARF | EUR | 698 | 17.5 | 53.2 | 139.9 | 35.8 | ELISA (% antigen) |
| WHI | EUR | 809 | 100 | 69.9 | 146.0 | 52.5 | Clotting assay (% activity) |
| FVIII (% activity) | |||||||
| ARIC | EUR | 10 708 | 53.0 | 54.3 | 124.1 | 30.6 | Clotting assay |
| AFR | 3 618 | 61.7 | 53.5 | 144.8 | 41.7 | ||
| CARDIA | EUR | 998 | 52.6 | 30.6 | 89.8 | 31.7 | Clotting assay |
| AFR | 632 | 55.6 | 29.2 | 103.5 | 38.7 | ||
| CHS | EUR | 4 009 | 56.2 | 72.8 | 120.8 | 36.7 | Clotting assay |
| AFR | 191 | 63.9 | 72.6 | 138.3 | 43.9 | ||
| MESA | EUR | 2 483 | 52.1 | 62.7 | 156.9 | 64.6 | Clotting assay |
| AFR | 1 638 | 53.8 | 62.2 | 178.0 | 74.6 | ||
| ASI | 764 | 7.7 | 62.4 | 157.9 | 57.2 | ||
| HIS | 1 418 | 51.5 | 61.0 | 161.8 | 63.4 | ||
| RS-I | EUR | 1 832 | 52.0 | 68.6 | 115.7 | 46.1 | Clotting assay |
| vWF (% antigen) | |||||||
| ARIC | EUR | 10 736 | 53.1 | 54.3 | 110.7 | 39.1 | ELISA |
| AFR | 3 625 | 61.8 | 53.5 | 131.4 | 51.1 | ||
| CARDIA | EUR | 1 002 | 52.6 | 30.6 | 89.9 | 36.4 | ELISA |
| AFR | 636 | 55.7 | 29.2 | 94.3 | 44.4 | ||
| FHS | EUR | 2 621 | 55.3 | 53.9 | 125.3 | 45.0 | ELISA |
| GeneSTAR | EUR | 991 | 52.5 | 42.6 | 78.7 | 46.1 | ELISA |
| AFR | 582 | 62.2 | 42.6 | 76.8 | 42.5 | ||
| LBC 1921 | EUR | 150 | 57.3 | 86.6 | 149.7 | 45.9 | ELISA |
| LBC 1936 | EUR | 706 | 47.9 | 72.5 | 122.6 | 37.8 | ELISA |
| MESA | EUR | 443 | 54.7 | 62.7 | 135.2 | 54.5 | ELISA |
| AFR | 193 | 64.8 | 62.2 | 156.1 | 64.8 | ||
| RS-I | EUR | 1 587 | 49.9 | 73.1 | 135.9 | 54.1 | ELISA |
| Factor and study acronym . | Ancestry . | No. of participants in study . | % Female . | Mean age, y . | Trait . | Assay/measure . | |
|---|---|---|---|---|---|---|---|
| Mean . | SD . | ||||||
| Fibrinogen (g/L) | |||||||
| ARIC49 | EUR | 10 757 | 53.1 | 54.3 | 2.90 | 1.21 | Clauss |
| AFR | 3 643 | 61.9 | 53.5 | 3.13 | 1.23 | ||
| CARDIA50 | EUR | 2 041 | 52.5 | 30.5 | 2.51 | 1.23 | Immunonephelometry |
| AFR | 1 709 | 56.9 | 29.4 | 2.66 | 1.23 | ||
| CHS51 | EUR | 4 034 | 56.2 | 72.8 | 3.13 | 1.22 | Clauss |
| AFR | 757 | 62.2 | 72.7 | 3.35 | 1.23 | ||
| FHS52,53 | EUR | 6 711 | 54.3 | 46.0 | 3.24 | 0.68 | Clauss |
| GeneSTAR54 | EUR | 1 091 | 51.2 | 41.2 | 3.51 | 0.98 | Modified Clauss |
| AFR | 641 | 61.9 | 40.6 | 3.80 | 1.12 | ||
| KORA S455,56 | EUR | 2 687 | 53.1 | 47.9 | 2.60 | 0.58 | Immunonephelometry |
| Korcula57 | EUR | 748 | 64.3 | 56.4 | 4.55 | 1.52 | Clauss |
| LBC 192158,59 | EUR | 466 | 57.4 | 79.1 | 3.59 | 0.86 | Clauss |
| LBC 193658,60 | EUR | 973 | 49.2 | 69.6 | 3.27 | 0.63 | Clauss |
| MESA61 | EUR | 2 483 | 52.1 | 62.7 | 3.35 | 0.7 | Immunonephelometry on the BN II nephelometer |
| AFR | 1 638 | 53.8 | 62.2 | 3.60 | 0.79 | ||
| ASI | 764 | 50.8 | 62.4 | 3.29 | 0.61 | ||
| HIS | 1 431 | 51.5 | 61.0 | 3.59 | 0.75 | ||
| PROCARDIS62 | EUR | 1 404 | 36.8 | 60.9 | 4.06 | 0.96 | Immunonephelometric |
| RS-I-163-65 | EUR | 1 114 | 59.0 | 70.2 | 2.70 | 1.26 | Prothrombin time |
| RS-I-363-65 | EUR | 972 | 46.7 | 72.4 | 3.96 | 0.89 | Prothrombin time |
| SCARF66 | EUR | 697 | 17.5 | 53.2 | 3.47 | 0.79 | Immunonephelometric |
| SHIP67 | EUR | 5 940 | 52.3 | 47.9 | 2.99 | 0.71 | Clauss |
| WGHS7,68 | EUR | 22 411 | 100 | 54.7 | 3.59 | 0.78 | Mass-based immunoturbidimetric assay |
| WHI69-71 | EUR | 1 204 | 100 | 69.6 | 3.06 | 0.86 | Clauss |
| FVII (% antigen or % activity)* | |||||||
| ARIC | EUR | 10 544 | 52.9 | 54.3 | 118.3 | 26.7 | Clotting assay (% activity) |
| AFR | 3 574 | 61.9 | 53.6 | 116.7 | 28.4 | ||
| CARDIA | EUR | 997 | 52.5 | 30.6 | 83.7 | 21.5 | Clotting assay (% activity) |
| AFR | 637 | 55.6 | 29.2 | 84.2 | 26.2 | ||
| CHS | EUR | 4 063 | 56.2 | 72.8 | 125.9 | 29.5 | Clotting assay (% activity) |
| AFR | 760 | 62.1 | 72.6 | 113.0 | 26.4 | ||
| FHS | EUR | 2 620 | 55.3 | 53.9 | 100.3 | 16.3 | ELISA (% antigen) |
| RS-I | EUR | 670 | 59.0 | 70.6 | 107.5 | 19.1 | Clotting assay (% activity) |
| SCARF | EUR | 698 | 17.5 | 53.2 | 139.9 | 35.8 | ELISA (% antigen) |
| WHI | EUR | 809 | 100 | 69.9 | 146.0 | 52.5 | Clotting assay (% activity) |
| FVIII (% activity) | |||||||
| ARIC | EUR | 10 708 | 53.0 | 54.3 | 124.1 | 30.6 | Clotting assay |
| AFR | 3 618 | 61.7 | 53.5 | 144.8 | 41.7 | ||
| CARDIA | EUR | 998 | 52.6 | 30.6 | 89.8 | 31.7 | Clotting assay |
| AFR | 632 | 55.6 | 29.2 | 103.5 | 38.7 | ||
| CHS | EUR | 4 009 | 56.2 | 72.8 | 120.8 | 36.7 | Clotting assay |
| AFR | 191 | 63.9 | 72.6 | 138.3 | 43.9 | ||
| MESA | EUR | 2 483 | 52.1 | 62.7 | 156.9 | 64.6 | Clotting assay |
| AFR | 1 638 | 53.8 | 62.2 | 178.0 | 74.6 | ||
| ASI | 764 | 7.7 | 62.4 | 157.9 | 57.2 | ||
| HIS | 1 418 | 51.5 | 61.0 | 161.8 | 63.4 | ||
| RS-I | EUR | 1 832 | 52.0 | 68.6 | 115.7 | 46.1 | Clotting assay |
| vWF (% antigen) | |||||||
| ARIC | EUR | 10 736 | 53.1 | 54.3 | 110.7 | 39.1 | ELISA |
| AFR | 3 625 | 61.8 | 53.5 | 131.4 | 51.1 | ||
| CARDIA | EUR | 1 002 | 52.6 | 30.6 | 89.9 | 36.4 | ELISA |
| AFR | 636 | 55.7 | 29.2 | 94.3 | 44.4 | ||
| FHS | EUR | 2 621 | 55.3 | 53.9 | 125.3 | 45.0 | ELISA |
| GeneSTAR | EUR | 991 | 52.5 | 42.6 | 78.7 | 46.1 | ELISA |
| AFR | 582 | 62.2 | 42.6 | 76.8 | 42.5 | ||
| LBC 1921 | EUR | 150 | 57.3 | 86.6 | 149.7 | 45.9 | ELISA |
| LBC 1936 | EUR | 706 | 47.9 | 72.5 | 122.6 | 37.8 | ELISA |
| MESA | EUR | 443 | 54.7 | 62.7 | 135.2 | 54.5 | ELISA |
| AFR | 193 | 64.8 | 62.2 | 156.1 | 64.8 | ||
| RS-I | EUR | 1 587 | 49.9 | 73.1 | 135.9 | 54.1 | ELISA |
Full cohort descriptions can be found in the supplemental Data.
ARIC, Atherosclerosis Risk in Communities Study; CARDIA, Coronary Artery Risk Development in Young Adults; CHS, Cardiovascular Health Study; ELISA, enzyme-linked immunosorbent assay; FHS, Framingham Heart Study; GeneSTAR, Genetic Study of Atherosclerosis Risk; KORA S4, Kooperative Gesundheitsforschung in der Region Augsburg; Korcula, Croatia-Korcula study; LBC 1921, Lothian Birth Cohort 1921; LBC 1936, Lothian Birth Cohort 1936; MESA, Multi-Ethnic Study of Atherosclerosis; PROCARDIS, Precocious Coronary Artery Disease Study; RS-I, Rotterdam Study-I; SCARF, Stockholm Coronary Artery Risk Factors; SD, standard deviation; SHIP, Study of Health in Pomerania; WGHS, Women’s Genome Health Study; WHI, Women’s Health Initiative.